



UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
 Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

12-12-2003

Date of Deposit

Signature

EL 964832244 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: DEAV2002/0087 US NP
 INVENTORS: Wendelin Frick et al
 TITLE: NOVEL HETEROCYCLIC
 FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS
 CONTAINING THESE COMPOUNDS, AND THE USE
 THEREOF

17548 U.S. PTO
 10/734573

APPLICATION ELEMENTS

1. <input checked="" type="checkbox"/>	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	
2. <input checked="" type="checkbox"/>	Specification (preferred arrangement set forth below)	Total Pages <input type="text" value="63"/>
3. <input type="checkbox"/>	Drawing(s) (35 U.S.C. 113)	Total Sheets <input type="text"/>
4. <input type="checkbox"/>	Oath or Declaration	Total Pages <input type="text" value="2"/>
a. <input checked="" type="checkbox"/>	Newly executed (Unexecuted)	
b. <input type="checkbox"/>	Copy from a prior application (37 CFR § 1.63(d))	
i. <input type="checkbox"/>	<u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).	
5. <input type="checkbox"/>	Power of Attorney	Total Pages <input type="text"/>
a. <input type="checkbox"/>	Newly executed (original or copy)	
b. <input type="checkbox"/>	Copy from a prior application (37 CFR § 1.63(d))	
6. <input type="checkbox"/>	Microfiche Computer Program (Appendix)	

7. Nucleotide and/or Amino Acid Sequence Submission

(if applicable, all necessary)

- a. Computer Readable Copy
- b. Paper Copy (identical to computer copy)
- c. Statement verifying identity of above copies

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part

of prior application no: _____, filed _____

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of U.S. Provisional Application No. 60/466,449, filed April 29, 2003 and claims priority to Germany Application No. 10258008.1-43, filed December 12, 2002. (The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS


- 7. Assignment Papers (cover sheet & document(s))
- 8. 37 CFR §3.73(b) Statement
(when there is an assignee)
- 9. Verified English Translation Document (if applicable)
- 10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
- 11. Preliminary Amendment
- 12. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- 13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
- 14. Certified Copy of Priority Document(s) (DE 10258008.1-43)
(if foreign priority is claimed)
- 15. Other: E-Pave Application Data Sheet

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)



Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0087 US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known

13040
121203
FEE TRANSMITTAL
for FY 2004

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** **(\$)** **770.00**

Application Number	NOT YET ASSIGNED
Filing Date	FILED HEREWITH
First Named Inventor	Wendelin Frick et al
Examiner Name	
Group / Art Unit	
Attorney Docket No.	DEAV2002/0087 US NP

METHOD OF PAYMENT (check all that apply)
 Check Credit Card Money Order Other None
 Deposit AccountDeposit Account Number **18-1982**Deposit Account Name **Aventis Pharmaceuticals Inc.**

The Commissioner is authorized to: (check all that apply)

 Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account
FEE CALCULATION**1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1001	770	2001	375
1002	340	2002	165
1003	530	2003	260
1004	770	2004	375
1005	160	2005	80
SUBTOTAL (1)		(\$)	770.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	12	-20**= 0	x 18.00 = 0
Independent Claims	1	- 3**= 0	x 86.00 = 0
Multiple Dependent			= 0

Large Entity	Small Entity	Fee Description
Fee Code	Fee (\$)	Fee Description
1202	18	2202 9 Claims in excess of 20
1201	86	2201 42 Independent claims in excess of 3
1203	290	2203 140 Multiple dependent claim, if not paid
1204	86	2204 42 **Reissue independent claims over original patent
1205	18	2205 9 **Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$0.00)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1051	130	2051	65 Surcharge - late filing fee or oath
1052	50	2052	25 Surcharge - late provisional filing fee or cover sheet
1053	130	1053	130 Non-English Specification
1812	2,520	1812	2,520 For filing a request for reexamination
1804	920*	1804	920* Requesting publication of SIR prior to Examiner action
1805	1,840*	1805	1,840* Requesting publication of SIR after Examiner action
1251	110	2251	55 Extension for reply within first month
1252	420	2252	205 Extension for reply within second month
1253	950	2253	465 Extension for reply within third month
1254	1,480	2254	725 Extension for reply within fourth month
1255	2,010	2255	985 Extension for reply within fifth month
1401	330	2401	160 Notice of Appeal
1402	330	2402	160 Filing a brief in support of an appeal
1403	290	2403	140 Request for oral hearing
1451	1,510	1451	1,510 Petition to institute a public use proceeding
1452	110	2452	55 Petition to revive - unavoidable
1453	1,330	2453	650 Petition to revive - unintentional
1501	1,330	2501	650 Utility issue fee (or reissue)
1502	480	2502	235 Design issue fee
1503	640	2503	315 Plant issue fee
1460	130	1460	130 Petitions to the Commissioner
1807	50	1807	50 Petitions related to provisional applications
1806	180	1806	180 Submission of Information Disclosure Stmt
8021	40	8021	40 Recording each patent assignment per property (times number of properties)
1809	770	2809	375 Filing a submission after final rejection (37 CFR § 1.129(a))
1810	770	2810	375 For each additional invention to be examined (37 CFR § 1.129(b))
1801	770	2801	375 Request for Continued Examination (RCE)
1802	900	1802	900 Request for expedited examination of a design application
Other fee (specify)			

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) **(\$)****SUBMITTED BY**

Name (Print/Type)	Barbara E. Kurys	Registration No. (Attorney/Agent)	34,650	Telephone	(908) 231-2965
Signature	<i>Barbara E. Kurys</i>			Date	12/12/03

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template